EUVIMEDEUVIMED entdecken
Open Access

Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials

Rebecca B Silva, Bin Cheng, Shing M Lee

Biometrics · 2026

DOI: 10.1093/biomtc/ujag161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2026. Verfasst von Rebecca B Silva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, United States. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Project Optimus, an initiative by the FDA’s Oncology Center of Excellence, seeks to reform the dose-optimization and dose-selection paradigm in oncology. We propose a dose-optimization design that considers plateau efficacy profiles, integrates pharmacokinetic data to inform the exposure-toxicity curve, and accounts for patient characteristics that may contribute to heterogeneity in response. The dose-optimization design is carried out in two stages. First, a toxicity-driven stage estimates a safe set of doses. Then, a dose-ranging efficacy-driven stage explores the set using response and patient characteristic data, employing Bayesian Sparse Group Selection to understand patient heterogeneity. Between stages, the design integrates pharmacokinetic data and uses futility assessments to identify the target population among the general phase I patient population. An optimal dose is recommended for each identified subpopulation within the target population. The simulation study demonstrates that a model-based approach to identifying the target population can be effective; patient characteristics relating to heterogeneity were identified, and different optimal doses were recommended for each identified target subpopulation. Most designs that account for patient heterogeneity are intended for trials where heterogeneity is known, and pre-defined subpopulations are specified. However, given the limited information at such an early stage, subpopulations should be learned through the design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsClinical Trials as TopicHumansDose-Response Relationship, DrugComputer SimulationBayes TheoremTreatment Effect HeterogeneityClinical Trials, Phase I as TopicModels, StatisticalResearch Design

Stichwörter der Autor:innen

biomarker identificationcancer clinical trialdose optimizationpatient heterogeneityphase I/II

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biostatistics, Columbia University Mailman School of Public Health, New York, NY 10032, United States.

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Silva, R. B., Cheng, B., & Lee, S. M. (2026). Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials. Biometrics. https://doi.org/10.1093/biomtc/ujag161

Vancouver

Silva RB, Cheng B, Lee SM. Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials. Biometrics. 2026. doi:10.1093/biomtc/ujag161

BibTeX
@article{Silva2026,
  author = {Silva, Rebecca B and Cheng, Bin and Lee, Shing M},
  title = {Seamless dose optimization design accounting for unknown patient heterogeneity in cancer clinical trials},
  journal = {Biometrics},
  year = {2026},
  doi = {10.1093/biomtc/ujag161}
}
Kostenlos starten →